The Waterloo Differential Acuity Test (WatDAT) – which was developed with funding from Fighting Blindness Canada – assesses ...

In diabetic macular edema, faricimab can improve visual acuity for treatment-naïve eyes or sustain vision for those ...

Kalaris Therapeutics offers differentiated approach to neovascular AMD with its lead candidate TH103. Click here to read my ...

Background There are limited treatment options to improve vision in patients with infantile nystagmus. We aimed to examine ...

In this video from the American Academy of Ophthalmology meeting, Michael W. Stewart, MD, discussed results from the phase 2 DAVIO 2 trial on Duravyu in neovascular age-related macular ...

TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injectionTH103 was ...

Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with ...

In a subgroup analysis of patients with polypoidal choroidal vasculopathy, aflibercept 8 mg achieved similar vision gains to ...

BCVA is inadequate for detecting visual disturbances in conditions like MacTel, which initially affect the parafoveal region.

Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...

The SERENA-6 trial shows a 54% reduced risk of death with camizestrant, with a median PFS of 16.6 months versus 9.2 months ...

The association between falls and visual function is shaped by living in homes with environmental hazards, according to a ...